New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:08 EDTALR, RHHBY, DHR, ABTAlere CEO departure sharpens focus on potential acquisition, says JMP Securities
After the CEO of Alere, Ron Zwanziger, resigned, JMP Securities thinks the resignation "brings the notion of Alere's potential acquisition front and center." The firm sees Alere as "a natural fit" for Roche (RHHBY), Abbott (ABT), or Danaher (DHR).
News For ALR;RHHBY;DHR;ABT From The Last 14 Days
Check below for free stories on ALR;RHHBY;DHR;ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 17, 2014
06:18 EDTDHRDanaher narrows FY14 EPS view to $3.67-$3.72, consensus $3.75
Subscribe for More Information
06:18 EDTDHRDanaher sees Q3 EPS 86c-89c, consensus 93c
Subscribe for More Information
06:04 EDTDHRDanaher reports Q2 EPS 95c, consensus 94c
Subscribe for More Information
July 16, 2014
16:05 EDTDHRDanaher to acquire Siemens Healthcare Diagnostics' clinical microbiology unit
Beckman Coulter, an indirect wholly-owned subsidiary of Danaher Corporation (DHR), announced that it has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics (SIEGY). The microbiology business operates with an installed base of over 6,000 instruments globally. The transaction is expected to close in 1Q15.
15:27 EDTDHRNotable companies reporting before tomorrow's open
Subscribe for More Information
14:01 EDTDHRDanaher technical comments before earnings
Subscribe for More Information
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
10:36 EDTABTTreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:25 EDTABTAbbott expects Global Nutrition sales to return to double digit growth in 2H14
Subscribe for More Information
09:23 EDTABTOn The Fly: Pre-market Movers
HIGHER: Time Warner (TWX), up 15% after company confirmed that it rejected an $80B takeover offer from 21st Century Fox (FOX, FOXA), as had been reported earlier this morning... Apple (AAPL), up 2% after announcing an enterprise mobile partnership with IBM (IBM), which is also up 2%... International Game (IGT), up 9.5% after agreeing to be acquired by GTECH for $4.7B in cash and stock... FireEye (FEYE), up 5% after shares upgraded at Goldman... Precision Drilling (PDS), up 4% after announcing strategic agreement with Schlumberger (SLB), upgraded at Deutsche Bank... Mellanox (MLNX), up 4.7% following upgrade at Jefferies. UP AFTER EARNINGS: Intel (INTC), up 5.4%... HCA Holdings (HCA), up 6%... Textron (TXT), up 3.2%... Abbott (ABT), up 1%. DOWN AFTER EARNINGS: PNC Financial (PNC), down 2.5%... MGIC Investment (MTG), down 3.6%. LOWER: Yahoo (YHOO), down 3% after downgraded at CRT Capital following second quarter earnings report... Ares Capital (ARCC), down 2.5% after filing to sell 11.85M shares of common stock... Nationstar (NSM), down 2.4% after downgraded at Wells Fargo... Walter Investment (WAC), which was also downgraded at Wells Fargo, down 1.6%.
09:17 EDTABTAbbott sees Q3 ongoing EPS 59c-61c, consensus 60c
Sees Q3 revenue growth in mid-single digits, consensus $5.63B. Expects neutral impact from foreign exchange.
09:16 EDTABTAbbott sees FY14 revenue growth in mid single digits, consensus $22.42B
Subscribe for More Information
09:03 EDTABTSanofi held talks on mature drugs with Abbott, Mylan, PE firms, Reuters says
Sanofi (SNY) has shopped an $8.5B portfolio of mature drugs to Abbott (ABT), Mylan (MYL) and private equity firms, according to Reuters, citing an internal company document circulated by the CGT union. Sanofi is considering whether to sell, carve out or create a joint venture for the portfolio of about 200 drugs, but a Sanofi spokesman said no decision has yet been made, the report noted. Reference Link
08:16 EDTABTLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
07:59 EDTABTTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:49 EDTABTAbbott reports Q2 Nutrition sales $1.73B; Reports Q2 Diagnostics sales $1.19B
Subscribe for More Information
07:47 EDTABTAbbott says it's on track for sales growth acceleration in 2H14
Subscribe for More Information
07:46 EDTABTAbbott raises FY14 ongoing EPS to $2.19-$2.29 from $2.16-$2.26, consensus $2.19
07:46 EDTABTAbbott reports Q2 ongoing EPS 54c, consenus 51c
Subscribe for More Information
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use